微軟新遊戲AI模型「Muse」亮相！即時生成遊戲畫面 卻引爆玩家正反論戰
知名遊戲媒體人 Geoff Keighley 日前在社群平台 X 上分享了一段由 Muse 生成的遊戲畫面，雖然看上去仍有些模糊，距離實際應用仍有一段距離，但已可清楚辨識角色動作、招式及敵人等，皆由 AI 運算而成。這些展示影片內容，AI 都是以 Ninja Theory 開發的多人對戰遊戲《嗜血邊緣》（Bleeding Edge）作為訓練素材。
Microsoft has announced "Muse," a generative AI model of a video game built by Microsoft in collaboration with Ninja Theory. This video shows entirely new sequences of Bleeding Edge gameplay created under human guidance. More here: https://t.co/AkM5JXtIeM pic.twitter.com/eSTbKXlleR
— Geoff Keighley (@geoffkeighley) February 19, 2025
微軟遊戲 AI 部門副總裁 Fatima Kardar 表示：「我們已將 Muse 應用於開發即時可玩的 AI 模型，且這項技術在未來有望同時造福玩家與遊戲開發者。」微軟也透露，Muse 目前仍處於早期開發階段，更多相關細節預計於 2025 年的遊戲開發者大會（GDC）上公布。
對於 AI 生成遊戲，社群反應不一。支持者認為，這有助於中小型團隊甚至獨立開發者減輕負擔，只需專注於程式碼、玩法設計等核心元素，其餘畫面與動作可交由 AI 生成，若價格合理，將大幅降低開發風險。
然而，反對者認為目前 Muse 展示的畫面缺乏靈魂，並擔憂可能取代大量遊戲美術與動畫師的工作。有玩家表示：「微軟只是想用 AI 取代開發人員」、「為什麼微軟不『生成』一些第一方獨佔遊戲」、「乾脆讓 AI 取代高層」、「科技公司正試圖抹煞藝術中的人性」、「這畫面看起來比獨立開發者 24 小時內做出的 Game Jam 作品還糟」。
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Microsoft Slashes 9,000 Jobs While Mark Zuckerberg's Meta Poaches $20 Million Worth Of AI Talent From OpenAI: Investor Warns Of 'Jealousy, Envy, And Helplessness' Among Tech Workers In Silicon Valley
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Microsoft Corp. (NASDAQ:MSFT) cut 9,000 jobs in its second 2025 layoff round while Meta Platforms Inc. (NASDAQ:META) and OpenAI ignite a talent war with compensation packages reaching $20 million annually, creating stark contrasts in Silicon Valley's artificial intelligence landscape. What Happened: The layoffs affect less than 4% of Microsoft's workforce across diverse teams and regions as the company maintains cost controls while investing $80 billion in AI data centers this fiscal year. Microsoft's gaming division, including Candy Crush parent King, eliminated 200 positions, marking the company's continued workforce reduction following 6,000 cuts in May. Don't Miss: Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — Now Raising at $3/Share Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. Meanwhile, Meta's aggressive talent acquisition has sparked unprecedented compensation inflation. Deedy Das, an AI investor at Menlo Ventures, told Business Insider that three machine-learning engineers at OpenAI and Anthropic received offers between $8 million and $20 million annually from Meta. 'There's a ton of ripple effects I'm hearing in the Valley,' Das said, describing widespread 'jealousy, envy, and helplessness' among tech workers not receiving such packages. The bidding war intensified after Meta recruited Scale CEO Alexandr Wang in a $14.3 billion deal and poached six star researchers from OpenAI for its new Meta Superintelligence Labs. OpenAI CEO Sam Altman claimed Meta offered $100 million signing bonuses, though Meta CTO Andrew Bosworth dismissed these claims as dishonest during a company meeting. Why It Matters: Roy Bahat of Bloomberg Beta noted the talent shortage drives extreme valuations, with only approximately 2,000 researchers capable of building foundational AI models globally. 'In my 20 years in tech, I have never seen as clearly defined a market for extraordinary talent,' Bahat said. The competition extends to universities, where companies pressure Ph.D. interns to abandon studies. 'They're pressuring them to drop out of school,' said Bill Aulet of MIT's Martin Trust Center for Entrepreneurship. Companies argue AI advances are happening so rapidly that graduation delays could cost career-defining opportunities. Microsoft's third quarter revenue of $70.07 billion, up 13% year-over-year, and Azure's 33% growth demonstrate continued AI demand despite workforce reductions. Read Next: $100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation. Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Here's how you can earn passive income with just $100. Photo courtesy: Tada Images / This article Microsoft Slashes 9,000 Jobs While Mark Zuckerberg's Meta Poaches $20 Million Worth Of AI Talent From OpenAI: Investor Warns Of 'Jealousy, Envy, And Helplessness' Among Tech Workers In Silicon Valley originally appeared on
Business Insider
2 hours ago
- Business Insider
Looking for Exposure to Microsoft Stock (MSFT)? Try These Two ETFs
Microsoft's (MSFT) growth prospects look robust, driven by its push into AI, cloud infrastructure, and enterprise software. Its AI-powered tools, such as Copilot, are now used by over 70% of Fortune 500 companies. Also, the tech giant is expanding its AI footprint globally, including a $400 million investment in Switzerland. Thus, investors looking for exposure to MSFT stock may consider investing in these two ETFs: Vanguard Information Technology ETF (VGT) and iShares Global Tech ETF (IXN). Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Let's take a deeper look at these two ETFs. Vanguard Information Technology ETF The VGT ETF provides investors with exposure to technology stocks, including companies in software, semiconductors, internet, and other technology-related sectors. This ETF tracks the MSCI U.S. Investable Market Index/Information Technology 25/50 Index. MSFT stock constitutes 15.11% of the ETF's holdings. Apart from MSFT, some of the top stocks in the VGT ETF are Nvidia (NVDA), Apple (AAPL), and Broadcom (AVGO). Overall, the ETF has $94.11 billion in assets under management (AUM). Also, it has an expense ratio of 0.09%. The VGT ETF has returned 38.2% in the past three months. Turning to Wall Street, the ETF has a Moderate Buy consensus rating. Of the 321 stocks held, 254 have a Buy, 60 have a Hold, and seven have a Sell ratings. At $725.62, the average VGT ETF price target implies a 7.66% upside potential. iShares Global Tech ETF The IXN ETF is ideal for long-term growth investors seeking global tech exposure. The ETF aims to track the performance of the S&P Global 1200 Information Technology Index, which includes tech giants from the U.S., Europe, and Asia. Importantly, MSFT accounts for 17.75% of IXN's total holdings. Some of the top holdings in IXN ETF include NVDA, Oracle (ORCL), and Palantir (PLTR). Overall, the ETF has $296.33 million in AUM and an expense ratio of 0.68%. Over the past three months, the IXN ETF has generated a return of 37.7%. On TipRanks, IXN has a Moderate Buy consensus rating based on 88 Buys, 32 Holds, and one Sell assigned in the last three months. At $97.95, the average IXN ETF price target implies 4.95% upside potential. Concluding Thoughts ETFs provide indirect exposure to Microsoft, reducing risk compared to investing directly in the stock. Furthermore, ETFs are a liquid and transparent way to participate in the market. Investors seeking ETF recommendations might consider VGT and IXN, as these ETFs offer exposure to MSFT stock.
Yahoo
2 hours ago
- Yahoo
Lunit partners with Microsoft to develop AI cancer diagnostic tools
South Korean AI company Lunit is collaborating with Microsoft to help bring its AI-powered diagnostics for cancer detection into clinical practice. According to Lunit, the partnership aligns with its vision to create AI tools that fit smoothly into everyday clinical care. The collaboration will involve Lunit and Microsoft's development of a tool for customising AI models that will be embedded into Microsoft's Azure cloud platform, thereby allowing Lunit users to customise their AI models using site-specific clinical data. Lunit adds that the approach will mitigate cross-site model performance variability, which it views as a key hurdle in the deployment of AI diagnostics in real-world clinical settings. The developer also plans to use Microsoft's agentic AI frameworks, which are designed to support intelligent task automation, to develop workflow automation tools. According to Lunit, these solutions will simplify clinical decision-making and improve operational efficiency for its AI cancer diagnostic tools. Lunit's AI tools include the SCOPE HER2 algorithm for human epidermal growth factor receptor 2 (HER2) biomarker evaluation in metastatic colorectal cancer (mCRC) patients undergoing HER2-targeted therapy, and INSIGHT DBT for identifying breast cancer in mammogram images. Lunit CEO Brandon Suh commented: 'Our collaboration with Microsoft enables us to bring our AI to more providers through trusted platforms like Microsoft Azure, helping us expand access in the US and beyond.' According to GlobalData analysis, the use of AI across healthcare is rapidly advancing, with the market projected to reach a valuation of around $19bn by 2027. Radiology has emerged as one of the most common areas in which AI is being applied – chiefly as a means to drive efficiencies and glean insights that humans evaluating radiologic images could miss. Naveen Valluri, general manager of health and life sciences data and AI at Microsoft, commented: 'With Microsoft Azure, we are shaping an ecosystem that supports partners like Lunit in delivering scalable AI innovations. 'By combining our infrastructure with clinical-grade AI developed in close collaboration with leaders like Lunit, we're accelerating the development of integrated solutions for radiology and beyond.' "Lunit partners with Microsoft to develop AI cancer diagnostic tools" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
